DeepSeek:
The growth of the leadless pacemaker market despite the recommendation for Conduction System Pacing (CSP) in lifelong pacing candidates stems from several key factors:
CSP (His bundle or left bundle branch pacing) is ideal for patients who require ventricular pacing long-term (e.g., AV block, bifascicular block) to avoid RV pacing-induced cardiomyopathy.
Leadless pacemakers (e.g., Micra™, Aveir™) are primarily used for single-chamber (VVI) pacing in patients who:
Need only occasional pacing (e.g., bradycardia, AF with slow ventricular response).
Have high infection risk (e.g., prior device infections).
Are poor candidates for transvenous leads (e.g., venous occlusion, limited vascular access).
No leads → Fewer complications (no lead fractures, venous obstruction, or tricuspid valve damage).
Lower infection risk (no surgical pocket, reducing pocket infections/endocarditis).
Faster recovery & minimal surgical burden (implanted via femoral vein, no incision).
Preferred for elderly/frail patients who may not need long-term CSP benefits.
Technical complexity: CSP requires skilled operators and has a steeper learning curve than leadless implants.
Higher acute procedural risk: His bundle pacing can have higher thresholds and lower success rates in some patients.
Long-term stability concerns: LBBP leads are still transvenous and may face late dislodgement/threshold issues.
If a patient only needs backup pacing (e.g., after TAVR or transient bradycardia), a leadless pacemaker may be preferable over committing to a lifelong CSP system.
Research is ongoing for leadless His bundle pacing, which could merge benefits of both technologies.
Currently, leadless pacemakers cannot achieve true CSP, but future iterations may change this.
While CSP is the preferred physiological pacing method for patients requiring lifelong ventricular pacing (to avoid RV pacing-induced dysfunction), leadless pacemakers address a different niche—patients needing simpler, safer, short-to-medium-term pacing without leads. The leadless market grows because it solves real clinical problems for a specific subset of patients, even if CSP remains the gold standard for others.
Gemini AI:
The increasing popularity of leadless pacemakers, despite the recognized benefits of Conduction System Pacing (CSP) to minimize harmful right ventricular (RV) pacing, can be attributed to several factors. These two technologies, while both representing advancements in cardiac pacing, serve different patient populations and offer distinct advantages.1
The growth of the leadless pacemaker market is driven by their unique benefits, which address a significant set of complications associated with traditional transvenous pacemakers.2
Elimination of Leads and Surgical Pockets: This is the primary and most significant advantage.3 Traditional pacemakers have leads (wires) that run from the device (implanted under the skin in the chest) into the heart.4 The surgical pocket in the chest and the leads themselves are a source of potential complications, including:
Infections5
Lead fracture or dislodgement6
Vein blockages7
Hematoma (a collection of blood)8
Tricuspid valve damage9
A visible bulge or scar on the chest
Restrictions on arm movement after implantation
Leadless pacemakers, which are self-contained devices implanted directly into the heart's right ventricle, eliminate all of these lead- and pocket-related complications.10
Minimally Invasive Procedure: The implantation of a leadless pacemaker is a less invasive procedure.11 It is performed via a catheter inserted through a vein in the leg (femoral vein), which reduces hospital stay and recovery time.12 Many patients can go home the same day and resume normal physical activity within a day or two.13
Growing Patient Population: The global population is aging, and with it comes a rising prevalence of cardiovascular diseases, including bradycardia (a slow heart rate) and other rhythm disorders.14 This demographic trend creates a large and growing market for all types of pacemakers, including leadless devices.15
Technological Advancements: The technology behind leadless pacemakers is continuously evolving.16 Initially, they were only capable of single-chamber ventricular pacing.17 However, recent innovations have introduced dual-chamber leadless systems that can provide atrioventricular (AV) synchrony, expanding their use to a broader range of patients.18 This continuous improvement in functionality makes them a more viable alternative to traditional pacemakers for more indications.
The premise of your question highlights a key distinction between these two technologies.
Conduction System Pacing (CSP), which includes His-bundle pacing (HBP) and left bundle branch pacing (LBBP), is an advanced form of pacing that aims to mimic the heart's natural electrical activation.19 By pacing the heart's own conduction system, CSP minimizes the harmful effects of pacing the right ventricle (RV), such as pacing-induced cardiomyopathy, and is particularly beneficial for patients with heart failure or conduction disorders.20
Leadless pacemakers, in their single-chamber form, pace the right ventricle.21 While studies have shown that leadless pacemakers may have a lower incidence of pacing-induced cardiomyopathy compared to traditional RV pacing, they still pace the RV and do not provide the physiological benefit of CSP.
In essence, CSP and leadless pacemakers are not always mutually exclusive solutions.22 The choice of which to use depends on the patient's specific condition and needs.
A patient who is a good candidate for CSP may not be a good candidate for a leadless pacemaker, especially if they require dual-chamber pacing or have an underlying conduction disease that CSP is designed to treat.
Conversely, a patient who needs single-chamber ventricular pacing and is at high risk for lead- or pocket-related complications (e.g., due to infection history, fragile skin, or specific anatomical issues) is an excellent candidate for a leadless pacemaker, even if CSP is not an option for them.
The growing market for leadless pacemakers reflects the fact that their benefits—primarily the avoidance of lead- and pocket-related complications and their minimally invasive nature—are highly valued by both patients and clinicians.23 While CSP offers a different set of physiological benefits, it still relies on traditional leads, which carry their own risks. As both technologies continue to advance, the landscape of cardiac pacing will likely become even more nuanced, with different devices serving different patient needs.